The rising incidence of hospital acquired infections (HAIs) has emerged as a major concern for governments, particularly across developing and underdeveloped countries. In first world countries such as the U.S., various regulations are in place for penalizing hospitals exhibiting a high incidence of HAIs. Such regulations augur well for the hospital acquired disease testing market in developed countries. In contrast, the absence of proper regulations and stringent policies limiting the adoption of molecular-biology-based diagnostics are restricting the expansion of the market across emerging nations.
Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1759
Increasing Awareness Regarding HAIs to Propel the Global Market
The increasing incidence of hospital acquired infections (HAI) is one of the key factors propelling the global hospital acquired disease testing market. For the prevention of these infections many countries such as the U.S. have issued rules and regulations to be mounted in the hospitals and clinics. For instance, the U.S. has regulated HHS Action Plan to reduce infections auqired in hospitals. These government plans and movements and increasing investments are expected to poise to growth of the global market of hospital acquired disease testing. Furthermore, the rising number of pathogens with drug-resistant abilities is foreseen to help the market expand. Numerous hospitals around the world are facilitating the pathogen detection procedures with improved surveillance culture. To prevent the transmission of diseases, various health organizations are demanding for effective hospital acquired disease testing solutions.
Factors such as growing concerns about control and prevention of nosocomial infections, increasing number of diseases that increase risk of hospital associated infections, initiatives taken up by governments to manage nosocomial infections, and increasing geriatric population are some of the key factors aiding the market’s expansion. Furthermore, the developing health facilities of developing countries of Asia Pacific are most likely fuel the global hospital acquired disease testing market.
Poor Regulations of Less Developed Countries Could Hinder the Market Growth
The majority of regulations regarding molecular-biology-based diagnostics remain un-updated, which can act as a restraining factor. Furthermore, the absence of control authorities and efficient control programs in less developed countries could hinder the market growth. For instance, African countries such as Nigeria do not have any effective programs or authority to prevent or control hospital acquired diseases.
Nevertheless, the rising health concerns among patients around the world are anticipated to help the market sustain its trajectory and grow over the forecast period. Furthermore, escalating number of urinary tract infection is anticipated fuel the demand for hospital acquires disease testing. Moreover, the increasing incidence of MRSA, pneumonia, and surgical site infection are expected to boost the market.